Literature DB >> 16725012

Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.

Anette Lykke Petri1, Estrid Høgdall, Ib Jarle Christensen, Susanne Krüger Kjaer, Jan Blaakaer, Claus Kim Høgdall.   

Abstract

The purpose of the present study was to evaluate preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer (EOC). Preoperative serum CA125 levels from 118 women with FIGO (International Federation of Gynaecology and Obstetrics) stage I EOC were analysed and the prognostic value was evaluated and compared with other prognostic factors (age, grade, substages, histologic type). By the Kaplan-Meier estimate we demonstrated that patients with stage I EOC and preoperative serum CA125 levels <65 U/mL had a significantly longer survival compared to stage I EOC patients with preoperative serum CA125 > or = 65 U/mL (p=0.01). The results from the present study may be useful for decision making respecting postoperative chemotherapy in stage I EOC patients. Serum CA125 levels might therefore be included as a prognostic factor in future clinical trials of stage I EOC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16725012     DOI: 10.1111/j.1600-0463.2006.apm_397.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

2.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

3.  Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.

Authors:  Hongyu Xie; Yan Hou; Jinlong Cheng; Margarita S Openkova; Bairong Xia; Wenjie Wang; Ang Li; Kai Yang; Junnan Li; Huan Xu; Chunyan Yang; Libing Ma; Zhenzi Li; Xin Fan; Kang Li; Ge Lou
Journal:  Oncotarget       Date:  2017-05-09

4.  Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Qingyi Wang; Xiaoling Feng; Xiaofang Liu; Siyu Zhu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

5.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

6.  Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.

Authors:  Szymon Piatek; Grzegorz Panek; Zbigniew Lewandowski; Mariusz Bidzinski; Dominika Piatek; Przemyslaw Kosinski; Miroslaw Wielgos
Journal:  J Ovarian Res       Date:  2020-09-02       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.